If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Eli Lilly and Company does not control, influence, or endorse this site, and the opinions, claims or comments expressed on this site should not be attributed to Eli Lilly and Company. Eli Lilly and Company is not responsible for the privacy policy of any third party web sites. We encourage you to read the privacy policy of every web site you visit.
Menu closed
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
ZypAdhera ® (olanzapine pamoate monohydrate)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
ZypAdhera Summary of Product Characteristics (SmPC)
ZypAdhera® (olanzapine pamoate): Storage and Stability
Reconstituted suspension should be used immediately; it is physically and chemically stable for 24 hours at 20-25°C. In-use storage is the responsibility of the user. Do not refrigerate or freeze.
If
the product is not used right away, it should be shaken vigorously
to re-suspend.1
Shelf
life once withdrawn from vial into syringe:
Once
withdrawn from vial into syringe, the suspension should be used
immediately.1
Chemical
and physical stability of the suspension in the vials has been
demonstrated for 24 hours at 20-25 °C. From a microbiological
point of view, the product should be used immediately. If not used
immediately, in-use storage times and conditions prior to use are the
responsibility of the user and would normally not be longer than 24
hours at 20-25°C.1
References
1.
ZypAdhera [summary of product characteristics] Eli Lilly Netherland
B.V., The Netherlands.
Date of Last Review:February 07, 2020
Are you satisfied with this content?
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com